Navigation Links
Inverseon Focuses on Mucous and Smoking Cessation
Date:1/12/2012

SAN FRANCISCO, Jan. 12, 2012 /PRNewswire/ -- Inverseon, Inc., a pharmaceutical company developing drug therapies for the treatment of pulmonary disorders, announced that while it anticipates that its asthma program will advance with non-dilutive grants, it is focused on smoking cessation as the initial indication for INV102.

William J. Garner, MD, Chairman, said, "The prioritization of smoking cessation, and also an inhaled COPD program, makes sense for Inverseon given the regulatory hurdles in key markets. We credit Dr. Glass for this refinement of our priorities. Mitchell Glass's extensive drug development background, relationships with the respiratory community, and experience with the strategic development and commercialization of therapeutics will be a major asset for Inverseon as the company advances its lead product (INV102) towards commercialization."

"Inverseon has provided critical support for the use of beta-adrenergic receptor inverse agonists for treating respiratory diseases. The founder's basic scientific breakthroughs provide a rational explanation for our previous success in developing carvedilol for heart failure while I was at SmithKline Beecham and provide a rationale for using INV102 for treating COPD. Two Phase II asthma trials are supportive of further development for chronic pulmonary diseases," said Dr. Glass. "We are now collaborating with granting agencies for further development of INV102 in asthma and preparing for expanded internal Phase II clinical trials demonstrating safety and efficacy of INV102 as a treatment to aid smoking cessation and chronic bronchitis."

About Inverseon, Inc.
Founded in 2004, Inverseon is a privately held company with product development programs in Phase II that target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as COPD and asthma. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

William J. Garner, MD
bill@inverseon.com  
http://www.inverseon.com  
(917) 653-0470

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
2. Nature article focuses on tinnitus treatment
3. ONR lecture focuses on Brazils growth in global science and technology
4. Florida Water Resources Annual Conference Focuses on Numeric Nutrient and Other Water Issues
5. Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform
6. Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate
7. Jivan Focuses on Solutions for Transcriptome Sequencing
8. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
9. Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009
10. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
11. ECBCs Environmental BioMonitoring Laboratory Focuses on the Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
Breaking Biology News(10 mins):